Autonomix Medical, Inc. Advances Toward U.S. Clinical Trials in 2025 with Completed Integration of Apex 6 Generator for Transvascular Ablation
Autonomix Medical (NASDAQ: AMIX) has achieved a significant milestone by completing the integration of the Apex 6 Radiofrequency Generator into its transvascular treatment platform, now branded as the Autonomix Sensing and RF Ablation System. This advancement keeps the company on schedule for its Investigational Device Exemption (IDE) submission and potential U.S. clinical trials initiation in 2025.
The integration follows the July 2024 licensing agreement with RF Innovations for the FDA-cleared Apex 6 Generator technology. The company aims to develop a treatment for pancreatic cancer pain, with the system showing promising early clinical results. Autonomix is working with RF Innovations' manufacturing partner to facilitate equipment development, targeting FDA De Novo clearance for commercialization in the U.S. market.
Autonomix Medical (NASDAQ: AMIX) ha raggiunto un traguardo significativo completando l'integrazione del Generatore di Radiofrequenza Apex 6 nella sua piattaforma di trattamento transvascolare, ora denominata Autonomix Sensing and RF Ablation System. Questo progresso mantiene l'azienda in linea con la programmazione per la presentazione della Investigational Device Exemption (IDE) e l'inizio di potenziali trial clinici negli Stati Uniti nel 2025.
L'integrazione segue l'accordo di licenza di luglio 2024 con RF Innovations per la tecnologia del Generatore Apex 6 approvata dalla FDA. L'azienda mira a sviluppare un trattamento per il dolore da cancro pancreatico, con il sistema che mostra risultati clinici preliminari promettenti. Autonomix sta collaborando con il partner di produzione di RF Innovations per facilitare lo sviluppo dell'attrezzatura, puntando all'approvazione FDA De Novo per la commercializzazione nel mercato statunitense.
Autonomix Medical (NASDAQ: AMIX) ha alcanzado un hito significativo al completar la integración del Generador de Radiofrecuencia Apex 6 en su plataforma de tratamiento transvascular, ahora denominada Autonomix Sensing and RF Ablation System. Este avance mantiene a la compañía en el cronograma para su presentación de Investigational Device Exemption (IDE) y el posible inicio de ensayos clínicos en EE. UU. en 2025.
La integración sigue el acuerdo de licencia de julio de 2024 con RF Innovations para la tecnología del Generador Apex 6 aprobado por la FDA. La compañía tiene como objetivo desarrollar un tratamiento para el dolor del cáncer de páncreas, con el sistema mostrando resultados clínicos preliminares prometedores. Autonomix está trabajando con el socio de fabricación de RF Innovations para facilitar el desarrollo del equipo, con el objetivo de obtener la aprobación De Novo de la FDA para la comercialización en el mercado estadounidense.
Autonomix Medical (NASDAQ: AMIX)는 Apex 6 라디오 주파수 발생기를 자사의 혈관 내 치료 플랫폼에 통합함으로써 중요한 이정표를 달성했으며, 이제 Autonomix Sensing and RF Ablation System이라는 브랜드로 알려져 있습니다. 이 발전은 회사가 Investigational Device Exemption (IDE) 제출 및 2025년 미국 임상 시험 개시를 위한 일정에 맞춰 진행되고 있음을 보여줍니다.
이번 통합은 FDA에서 승인된 Apex 6 발생기 기술에 대한 RF Innovations와의 2024년 7월 라이센스 계약에 이어 이루어졌습니다. 회사는 췌장암 통증 치료 개발을 목표로 하고 있으며, 이 시스템은 초기 임상 결과에서 유망한 성과를 보이고 있습니다. Autonomix는 RF Innovations의 제조 파트너와 협력하여 장비 개발을 촉진하고, 미국 시장에서 상용화를 위한 FDA De Novo 승인을 목표로 하고 있습니다.
Autonomix Medical (NASDAQ: AMIX) a atteint une étape significative en complétant l'intégration du Générateur de Radiofréquence Apex 6 dans sa plateforme de traitement transvasculaire, désormais appelée Autonomix Sensing and RF Ablation System. Cette avancée maintient l'entreprise sur la bonne voie pour sa soumission de Investigational Device Exemption (IDE) et le potentiel lancement d'essais cliniques aux États-Unis en 2025.
L'intégration fait suite à l'accord de licence de juillet 2024 avec RF Innovations pour la technologie du Générateur Apex 6 approuvée par la FDA. L'entreprise vise à développer un traitement pour la douleur liée au cancer du pancréas, le système montrant des résultats cliniques préliminaires prometteurs. Autonomix collabore avec le partenaire de fabrication de RF Innovations pour faciliter le développement de l'équipement, visant une approbation FDA De Novo pour la commercialisation sur le marché américain.
Autonomix Medical (NASDAQ: AMIX) hat einen bedeutenden Meilenstein erreicht, indem es die Integration des Apex 6 Radiofrequenzgenerators in seine transvaskuläre Behandlungsplattform abgeschlossen hat, die jetzt als Autonomix Sensing and RF Ablation System bezeichnet wird. Dieser Fortschritt hält das Unternehmen im Zeitplan für die Einreichung der Investigational Device Exemption (IDE) und den möglichen Beginn klinischer Studien in den USA im Jahr 2025.
Die Integration folgt dem Lizenzvertrag von Juli 2024 mit RF Innovations für die von der FDA genehmigte Technologie des Apex 6 Generators. Das Unternehmen hat das Ziel, eine Behandlung für die Schmerzen bei Bauchspeicheldrüsenkrebs zu entwickeln, wobei das System vielversprechende frühe klinische Ergebnisse zeigt. Autonomix arbeitet mit dem Fertigungspartner von RF Innovations zusammen, um die Entwicklung der Ausrüstung zu erleichtern, mit dem Ziel, eine FDA De Novo Genehmigung für die Vermarktung auf dem US-Markt zu erhalten.
- Successfully completed integration of FDA-cleared Apex 6 Generator technology
- On track for IDE submission and clinical trials in 2025
- Early clinical results demonstrate promising treatment potential
- Strategic partnership with RF Innovations' manufacturing partner established
- Product still requires FDA De Novo clearance
- Clinical trials haven't started yet
- Revenue generation dependent on future regulatory approvals
Insights
Autonomix's integration milestone represents measurable progress in their development pathway for a novel nerve-targeted treatment platform. By successfully completing the design lock for the Apex 6 RF Generator into their transvascular treatment platform, the company has maintained their timeline toward an IDE submission and possible clinical trials initiation in 2025.
This approach demonstrates strategic resource allocation. Rather than developing a proprietary generator from scratch, Autonomix licensed an existing FDA-cleared technology from RF Innovations in July 2024. This decision likely saved significant development time and regulatory hurdles by leveraging a proven component, allowing the company to focus resources on their proprietary sensing and ablation catheter technology.
The development targets pancreatic cancer pain - a significant unmet medical need. Pancreatic cancer patients often experience severe pain that dramatically impacts quality of life, with effective treatment options currently available.
While this announcement confirms continued progress, investors should note several key considerations: 1) This is a pre-clinical development milestone, not clinical validation; 2) The timeline for IDE submission and potential trials remains in 2025 - no acceleration of previous projections; 3) The company is pursuing a De Novo regulatory pathway, which typically has longer timelines than 510(k) clearances but shorter than PMAs.
For a company with a
This integration milestone carries regulatory significance within Autonomix's development pathway. By incorporating an already FDA-cleared component (the Apex 6 Generator) into their system, the company has implemented a classic regulatory risk-mitigation strategy. This approach potentially simplifies certain aspects of their IDE submission by leveraging an established safety profile for the energy delivery component.
The company's timeline targeting IDE submission in 2025 appears reasonable given this milestone completion. However, the pathway to market still involves multiple critical regulatory steps: 1) IDE approval by FDA to begin clinical trials; 2) Successful completion of those trials with appropriate safety and efficacy endpoints; and 3) De Novo classification request approval.
The De Novo pathway mentioned is noteworthy - this confirms Autonomix believes their technology has no substantially equivalent predicate device on the market. While this opens potential competitive advantages, it also typically requires more robust clinical evidence than a 510(k) submission would.
For pancreatic cancer pain, regulatory requirements will likely focus on demonstrating meaningful pain reduction without unacceptable safety risks. The transvascular approach may require particular safety validation around vascular access and potential damage to non-target tissues.
The completion of design lock is indeed significant as it indicates finalization of the device configuration that will proceed to clinical evaluation. Post-design lock changes typically require substantial justification and potentially additional preclinical testing, so this milestone suggests confidence in their current design's performance in preclinical evaluations.
Company successfully meets key milestone with design lock that integrates and finalizes enhancements to its licensed Apex 6 Radiofrequency (“RF”) Generator
On track for Investigational Device Exemption (“IDE”) submission and, if approved, U.S. clinical trial initiation in 2025 for pancreatic cancer pain
Milestone advances proprietary sensing and ablation catheter technology into a fully integrated transvascular treatment platform
THE WOODLANDS, TX, March 14, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today announced it has completed the integration and design enhancements of the Apex 6 Generator into a fully integrated transvascular treatment platform, now rebranded as the Autonomix Sensing and RF Ablation System. The completion of this important milestone allows the Company to remain on track for submitting its IDE application with the U.S. FDA and potentially initiate clinical trials in the United States in 2025.
In July 2024, Autonomix completed its transaction with RF Innovations, Inc., a privately held medical technology company, to license the intellectual property to its Apex 6 Generator, an existing FDA-cleared technology. The Apex 6 Generator aligned with the RF generator specifications required for Autonomix’s Sensing and RF Ablation System and provided a cost effective, de-risked approach to accelerating platform development. Following a rigorous preclinical assessment, the Company has now fully optimized the design for its first-in-class sensing and ablation device.
“There is an urgent need to transform the treatment paradigm for pancreatic cancer patients, offering effective pain relief and improving quality of life,” commented Brad Hauser, CEO of Autonomix. “Our early clinical results have consistently demonstrated the potential to address this unmet medical need, and the successful integration of our RF Generator is a critical step forward. With our IDE submission targeted for 2025, we are closer than ever to bringing this innovation into the clinic and advancing toward potential FDA De Novo clearance. We remain committed to unlocking significant value for both patients and stakeholders as we progress toward commercialization.”
As previously announced, Autonomix is collaborating with RF Innovations’ manufacturing partner, who was incorporated into the Company’s manufacturing supply chain, to facilitate equipment development.
The Company expects to submit an IDE and commence U.S. clinical trials in 2025 to support a labeling indication to commercialize the Autonomix Sensing and RF Ablation System in the U.S. as a treatment for pancreatic cancer pain.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company’s first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with approximately 3,000 times greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Forward Looking Statements
Some of the statements in this release are “forward-looking statements,” which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the timing of the Company’s submission of an IDE, the timing of the commencement of U.S. clinical trials, and the potential of the technology to treat cancerous tumors and the pain associated with pancreatic cancer. Such forward-looking statements can be identified by the use of words such as “should,” “might,” “may,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “forecasts,” “expects,” “plans,” and “proposes.”
Although Autonomix believes that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements. You are urged to carefully review and consider any cautionary statements and other disclosures, including the statements made under the heading “Risk Factors” and elsewhere in the Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on May 31, 2024 and in other filings made by us from time to time with the SEC. Forward-looking statements speak only as of the date of the document in which they are contained and Autonomix does not undertake any duty to update any forward-looking statements except as may be required by law.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
FAQ
When will Autonomix Medical (AMIX) begin clinical trials for its pancreatic cancer pain treatment?
What is the purpose of Autonomix Medical's (AMIX) Sensing and RF Ablation System?
What recent milestone has Autonomix Medical (AMIX) achieved with the Apex 6 Generator?
When did AMIX acquire the license for the Apex 6 Generator technology?
